Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T cells for T cell malignancies
Author:
Publisher
Elsevier BV
Subject
Drug Discovery,Pharmacology,Genetics,Molecular Biology,Molecular Medicine
Reference38 articles.
1. Chimeric antigen receptors for T-cell malignancies;Scherer;Front Oncol.,2019
2. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies;Gomes-Silva;Blood,2017
3. Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies;Png;Blood Adv.,2017
4. An “off-the-shelf” fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies;Cooper;Leukemia,2018
5. Donor-derived CD7 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia: first-in-human, phase I trial;Pan;J. Clin. Oncol.,2021
Cited by 35 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Therapeutic potentials of adoptive cell therapy in immune-mediated neuropathy;Journal of Autoimmunity;2024-12
2. Targeting CD45 by gene-edited CAR T cells for leukemia eradication and hematopoietic stem cell transplantation preconditioning;Molecular Therapy: Oncology;2024-09
3. Chimeric antigen receptor-induced antigen loss protects CD5.CART cells from fratricide without compromising on-target cytotoxicity;Cell Reports Medicine;2024-07
4. CD37 is a safe chimeric antigen receptor target to treat acute myeloid leukemia;Cell Reports Medicine;2024-06
5. INSPIRED Symposium Part 5: Expanding the Use of CAR T Cells in Children and Young Adults;Transplantation and Cellular Therapy;2024-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3